SCHEMBL4089995

SCHEMBL4089995

CCCC=Cc1ccccc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.43
ALDH1A1 P00352 2/20 0.43
ALOX15 P16050 1/20 0.43
CYP2C9 P11712 2/20 0.42
HPGD P15428 1/20 0.42
CXCR5 P32302 2/20 0.41
GRIK1 P39086 1/20 0.41
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA3 P42263 1/20 0.41
GRIA4 P48058 1/20 0.41
GRIK2 Q13002 1/20 0.41
GRIK3 Q13003 1/20 0.41
CYSLTR2 Q9NS75 2/20 0.41
CYSLTR1 Q9Y271 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
TLR8 Q9NR97 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11213197 0.90 PDE5A (0.49) PTPN1ALDH1A1CYP2C9HPGDCYSLTR2
SCHEMBL11213193 0.90 PDE5A (0.49) PTPN1ALDH1A1CYP2C9HPGDCYSLTR2
SCHEMBL10496500 0.89 CYSLTR2 (0.53) ALDH1A1ALOX15CYP2C9HPGDCYSLTR2
SCHEMBL10496494 0.89 CYSLTR2 (0.53) ALDH1A1ALOX15CYP2C9HPGDCYSLTR2
SCHEMBL14672873 0.87 CYSLTR2 (0.55) ALDH1A1ALOX15CYSLTR2CYSLTR1KDM4E
SCHEMBL22439053 0.87 CYSLTR2 (0.55) ALDH1A1ALOX15CYSLTR2CYSLTR1KDM4E
SCHEMBL9504864 0.87 CYSLTR2 (0.55) ALDH1A1ALOX15CYSLTR2CYSLTR1KDM4E
SCHEMBL22439056 0.87 CYSLTR2 (0.55) ALDH1A1ALOX15CYSLTR2CYSLTR1KDM4E
SCHEMBL9504870 0.87 CYSLTR2 (0.55) ALDH1A1ALOX15CYSLTR2CYSLTR1KDM4E
SCHEMBL966581 0.86 ALDH1A1 (0.46) PTPN1ALDH1A1ALOX15CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230051453-A1 BIOSYNTHETIC PLATFORM FOR THE PRODUCTION OF OLIVETOLIC ACID AND ANALOGUES OF OLIVETOLIC ACID THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-02-16 US disclosed
EP-4087932-A1 BIOSYNTHETIC PLATFORM FOR THE PRODUCTION OF OLIVETOLIC AVID AND ANALOGUES OF OLIVETOLIC ACID The Regents of the University of California (US) 2022-11-16 EP disclosed
EP-3377473-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX Pharmaceuticals, Inc. (US) 2018-09-26 EP disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
EP-1680109-A4 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS INC (US) 2009-05-06 EP disclosed
US-20080312237-A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same RENOVIS, INC. 2008-12-18 US disclosed
US-7432281-B2 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same RENOVIS, INC. (US) 2008-10-07 US disclosed
EP-1680109-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Renovis, Inc. (US) 2006-07-19 EP disclosed
US-20050222200-A1 AMIDE DERIVATIVES AS ION CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2005-10-06 US disclosed
WO-2005046683-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2005-05-26 WO disclosed
EP-1280757-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-05 EP disclosed
WO-2001083438-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 PTPN1 970/4885ALDH1A1 836/4885ALOX15 4747/4885
US-20080312237-A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same TRPV1, TRPA1, TRPV2 PTPN1 2103/4885ALDH1A1 1821/4885ALOX15 443/4885
US-20050222200-A1 AMIDE DERIVATIVES AS ION CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 PTPN1 1578/4885ALDH1A1 1496/4885ALOX15 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.